- Home
- GMAB vs OVV Comparison
GMAB vs OVV Comparison
Compare GMAB & OVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GMAB | OVV |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 20.0B |
| IPO Year | 2008 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GMAB | OVV |
|---|---|---|
| Price | $53.20 | $63.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 25 |
| Target Price | $65.11 | ★ $81.95 |
| AVG Volume (30 Days) | ★ 6.1M | 3.4M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 1.95% |
| EPS Growth | N/A | ★ 13.54 |
| EPS | N/A | ★ 1.36 |
| Revenue | N/A | ★ $8,908,000,000.00 |
| Revenue This Year | $27.36 | $17.07 |
| Revenue Next Year | $21.44 | N/A |
| P/E Ratio | ★ $1.90 | $45.26 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.62 | $36.81 |
| 52 Week High | $59.97 | $73.62 |
Technical Indicators
Market Signals| Indicator | GMAB | OVV |
|---|---|---|
| Relative Strength Index (RSI) | 64.30 | 42.71 |
| Support Level | $25.91 | $56.66 |
| Resistance Level | $59.97 | $67.45 |
| Average True Range (ATR) | 3.21 | 2.41 |
| MACD | -0.05 | -1.15 |
| Stochastic Oscillator | 65.97 | 27.26 |
Price Performance
Historical ComparisonAbout GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About OVV Ovintiv Inc. (DE)
Ovintiv is an independent oil and gas producer focused on Canada's Montney and the US' Permian basins. Historically, it has been an acquisitive producer across numerous basins and plays but has divested and exited all but two. It remains an active buyer in the remaining footprint. The firm estimates that it has up to 20 and 15 years of inventory remaining in the Montney and Permian basins, respectively.